Role of oral sildenafil in severe pulmonary arterial hypertension: Clinical efficacy and dose response relationship

International Journal of Cardiology

Volumn 120, Issue 3, 2007, Pages 306-313

  Garg, Naveen ^a   Sharma, Mukesh Kumar ^a   Sinha, Nakul ^a  

^a SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Eisenmenger syndrome; Idiopathic pulmonary hypertension; Phosphodiesterase inhibitors; Pulmonary arterial hypertension; Pulmonary vasodilator; Sildenafil

Indexed keywords

PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL;

ADOLESCENT; ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; BODYACHE; CLINICAL ARTICLE; DISEASE SEVERITY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; ECHOCARDIOGRAPHY; EISENMENGER COMPLEX; EYE EXAMINATION; EYE FUNDUS; FEMALE; FOLLOW UP; FUNCTIONAL ASSESSMENT; HEADACHE; HEART CATHETERIZATION; HEMOPTYSIS; HOT FLUSH; HUMAN; HYPOTENSION; IDIOPATHIC DISEASE; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; MAXIMUM TOLERATED DOSE; PAIN; PATIENT MONITORING; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RHINORRHEA; SCHOOL CHILD; SIX MINUTE WALK TEST; THORAX PAIN; TREATMENT OUTCOME; TREATMENT RESPONSE; VISUAL DISORDER; WALKING;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; CHEST PAIN; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; ECHOCARDIOGRAPHY; EISENMENGER COMPLEX; EXERCISE TEST; FEMALE; FOLLOW-UP STUDIES; HEART CATHETERIZATION; HEMOPTYSIS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; OXYGEN; PHOSPHODIESTERASE INHIBITORS; PIPERAZINES; PURINES; SULFONES;

EID: 34447519921     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2006.10.017     Document Type: Article

References (44)

1. Galie N., Seeger W., Naeije R., Simonneau G., and Rubin L.J. Comparative analysis of clinical trials and evidence based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol 43 Suppl 12 (2004) 81-88
2. Humbert M., Sitbon O., and Simonneau G. Drug therapy: treatment of pulmonary arterial hypertension. N Engl J Med 351 (2004) 1425-1436
3. Singh B., Gupta R., Punj V., et al. Sildenafil in the management of primary pulmonary hypertension. Indian Heart J 54 (2002) 297-300
4. Bharani A., Mathew V., Sahu A., and Lunia B. The efficacy and tolerability of sildenafil in patients with moderate to severe pulmonary hypertension. Indian Heart J 55 (2003) 55-59
5. Kothari S.S., and Duggal B. Chronic oral sildenafil therapy in severe pulmonary artery hypertension. Indian Heart J 54 (2002) 404-409
6. Sastry B.K.S., Narasimhan C., Reddy N.K., and Raju B.S. Clinical efficacy of sildenafil in primary pulmonary hypertension - a randomized, placebo controlled, double blind, crossover study. J Am Coll Cardiol 43 (2004) 1149-1153
7. Galie N., Ghofrani H.A., Torbicki A., et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353 (2005) 2148-2157
8. Humpl T., Reyes J.T., Holtby H., Stephens D., and Adatia I. Beneficial effect of oral sildenafil therapy on childhood pulmonary arterial hypertension. Circulation 111 (2005) 3274-3280
9. Karatza A.A., Bush A., and Magee A.G. Safety and efficacy of sildenafil therapy in children with pulmonary hypertension. Int J Cardiol 100 (2005) 267-273
10. Kataoka M., Satoh T., Manabe T., et al. Oral sildenafil improves primary pulmonary hypertension refractory to epoprostenol. Circ J 69 (2005) 461-465
11. Schulze-Neick I., Hartenstein P., Li J., et al. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease. Circulation 108 suppl II (2003) 167-II-173
12. Mikhaila G.W., Prasada S.K., Lia W., et al. Clinical and haemodynamic effects of sildenafil in pulmonary hypertension: acute and mid-term effects. Eur Heart J 25 (2004) 431-436
13. Zhao L., Mason L.A., Strange J.W., Walker H., and Wilkins M.R. Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation 107 (2003) 234-237
14. Corbin J.D., and Francis S.H. Cyclic GMP phosphodieserase-5: target of sildenafil. J Biol Chem 274 (1999) 13729-13732
15. Tantini B., Manes A., Fiumana E., et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 100 (2005) 131-138
16. Ichinose F., Erana-Gracia J., Hromi J., et al. Nebulized sildenafil is a selective pulmonary vasodilator in lambs with acute pulmonary hypertension. Crit Care Med 29 (2001) 1000-1005
17. Zhao L., Mason N.A., Morrel N.W., et al. Sildenafil inhibits hypoxia induced pulmonary hypertension. Circulation 104 (2001) 424-428
18. Abrams D., Neick I.S., and Magee A.G. Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension. Heart 84 (2000) e4
19. Michelakis E., Tymchak W., Lien D., Webster L., Hashimoto K., and Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 105 (2002) 2398-2403
20. Walsh C.A., and Wilde P. Acquired valve disease. In: Walsh C.A., and Wilde P. (Eds). Practical Echocardiography. 1st ed (1999), Greenwich Medical Media Ltd, London, UK 63-89
21. Feigenbaum H. Acquired valvular heart disease. In: Feigenbaum H. (Ed). Echocardiography. 5th ed (1994), Lea & Febiger Co, Philadelphia, USA 239-349
22. Borgeson D.D., Seward J.B., Muller Jr. F.A., Oh J.K., and Tajik J. Frequency of Doppler measurable pulmonary artery pressures. J Am Soc Echocardiogr 9 (1996) 832-837
23. Grossman W. Blood flow measurement: the cardiac output. In: Grossman W., and Baim D.S. (Eds). Cardiac Catheterization, Angiography and Intervention. 4th ed (1991), Lea & Febiger Co, Philadelphia, USA 105-122
24. Grossman W. Clinical measurement of vascular resistance and assessment of vasodilator drugs. In: Grossman W., and Baim D.S. (Eds). Cardiac Catheterization, Angiography and Intervention. 4th ed (1991), Lea & Febiger Co, Philadelphia, USA 143-151
25. Graham T.P., and Gutgesell H.P. Ventricular septal defects. In: Emmanouilides G.C., Riemenschneider T.A., Allen H.D., and Gutgesell H.P. (Eds). Moss and Adam's heart disease in infants, children, and adolescents including the fetus and young adults. 5th ed (1995), Williams & Wilkins, Baltimore, Maryland, USA 724-746
26. Neutze J.M., Ishikawa T., Clarkson P.M., Calder A.I., Barratt-Boyes B.G., and Kerr A.R. Assessment and follow-up of patients with ventricular septal defect and elevated pulmonary vascular resistance. Am J Cardiol 63 (1989) 327-331
27. Enright P.L., and Sherrill D.L. Reference equations for the six minute walk in healthy adults. Am J Respir Crit Care Med 158 (1998) 1384-1387
28. Miyamoto S., Nagaya N., Satos T., et al. Clinical correlates and prognostic significance of six minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 161 (2000) 487-492
29. Sanchez L.S., de la Monte S.M., Filippov G., Jones R.C., Zapol W.M., and Bloch K.D. Cyclic-GMP-specific phosphodiesterase (PDE5) gene expression is regulated during rat pulmonary development. Pediatr Res 43 (1998) 163-168
30. Chockalingam A., Gnanavelu G., Venkatesan S., et al. Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int J Cardiol 99 (2005) 91-95
31. Agapito A.F., Sousa L., Oliveira J.A., Feliciano J., Cacela D., and Quininha J. Eisenmenger syndrome in adult - experience with new drug for the treatment of pulmonary hypertension. Rev Port Cardiol 24 3 (2005) 421-431
32. Ghofrani H.A., Wiedemann R., Rose F., et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomized controlled trial. Lancet 360 (2002) 895-900
33. Derchi G., Forni G.L., Formisano F., et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 90 (2005) 452-458
34. Alaeddini J., Uber P.A., Park M.H., Scott R.L., Ventura H.O., and Mehra M.R. Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am J Cardiol 94 (2004) 1475-1477
35. Jeffery T.K., and Morell N.W. Molecular and cellular basis of pulmonary vascular remodeling in pulmonary hypertension. Prog Cardiovasc Dis 45 (2002) 173-202
36. Sitbon O., Humbert M., Nunes H., et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 21 (2002) 780-788
37. Weimann J., Ullrich R., Hromi J., et al. Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology 92 (2000) 1702-1712
38. Prasad S., Wilkinson J., and Gatzoulis M.A. Sildenafil in primary pulmonary hypertension. N Engl J Med 343 (2000) 1342
39. Jackson G., Benjamin N., Jackson N., et al. Effect of sildenafil citrate on human hemodynamics. Am J Cardiol 83 (1999) 13C-20C
40. Wilkens H., Guth A., König J., et al. Effect of inhaled iloprost plus oral sildenafil in patients with primary pulmonary hypertension. Circulation 104 (2001) 1218-1222
41. Bigatello L.M., Hess D., Dennehy K.C., et al. Sildenafil can increase the response to inhaled nitric oxide. Anesthesiology 92 (2000) 1827-1829
42. Bhatia S., Frantz R.P., Severson C.J., Durst L.A., and McGoon M.D. Immediate and long-term hemodynamic and clinical effects of sildenafil in patients with pulmonary arterial hypertension receiving vasodilator therapy. Mayo Clin Proc 78 10 (2003) 1207-1213
43. Ghofrani H.A., Wiedemann R., Rose F., et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 136 (2002) 515-522
44. Eardley L., Ellis P., Bootell M., and Wulff M. Onset and duration of action of sildenafil citrate for the treatment of erectile dysfunction. Br J Clin Pharmacol 53 (2000) 61S-65S